[Effect of extract of Ginkgo biloba on doxorubicin-associated cardiotoxicity in patients with breast cancer].
OBJECTIVE
To study the effect of extract of Ginkgo biloba (Egb761) on doxorubicin-associated cardiotoxicity in patients with breast cancer (BC).


METHODS
Sixty BC patients in stage IV were randomly assigned to two groups, the control group was treated with chemotherapy, using 4 cycles of PA protocol alone and the treated group with the same chemotherapy and Egb761. Changes in electrocardiogram (ECG), myocardial enzyme spectrum (MES) and ultrasono-cardiogram (USCG) before and after treatment were observed.


RESULTS
After treatment, the incidence of abnormal ECG was lower in the treated group than in the control group (6.7% vs 30.0%); significant differences were found between the two groups in the parameters of MES (P< 0.05); USCG showed significant difference between the two groups in left ventricular diastolic diameter (LVDd), left ventricular systolic diameter (LVDs), ratio of early and late diastolic transmitral peak flow velocity (E/A) and fractional shortening (FS), while there was no significant difference in ejection fraction (EF).


CONCLUSIONS
Egb761 is an ideal drug for preventing and reducing the acute doxorbincin-induced cardiotoxicity; it could also be helpful for alleviating the chronic cardiotoxicity.
Yi
Shan-Yong
SY
Department of Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an.
Nan
Ke-Jun
KJ
Chen
Sheng-Jie
SJ
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy; D009202:Cardiomyopathies / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D020441:Ginkgo biloba / Q000737:chemistry; D006801:Humans; D008875:Middle Aged; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology / Q000517:prevention & control; D000096983:Ginkgo Extract
D004317:Doxorubicin; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract